<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pruritus: Therapies for localized pruritus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pruritus: Therapies for localized pruritus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pruritus: Therapies for localized pruritus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sara B Fazio, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gil Yosipovitch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert P Dellavalle, MD, PhD, MSPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 07, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H8354347">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pruritus is a common symptom that may be localized (affecting limited areas of skin) or generalized and occurs in a wide variety of clinical settings, such as dermatologic, systemic, neuropathic, or psychiatric disease. In addition to physical effects (eg, skin injury, secondary infections, scarring, and sleep deprivation), pruritus can contribute to emotional disturbances, such as agitation and depression [
         <a href="#rid1">
          1
         </a>
         ]. In severe cases, pruritus can be incapacitating.
        </p>
        <p>
         The inciting factor for localized pruritus and the severity of symptoms influence the approach to treatment. Examples of causes of localized pruritus include inflammatory, dermatologic disorders; burns; scars; and forms of neuropathic itch. (See
         <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">
          "Pruritus: Etiology and patient evaluation", section on 'Potential causes'
         </a>
         .)
        </p>
        <p>
         While amelioration of pruritus is sometimes easily attained, treatment is challenging in some patients. A wide variety of therapies have been used for pruritus; however, efficacy data are limited for many treatment options  (
         <a class="graphic graphic_table graphicRef50432 graphicRef63221" href="/z/d/graphic/50432.html" rel="external">
          table 1A-B
         </a>
         ).
        </p>
        <p>
         The treatment of localized pruritus will be discussed here. The management of generalized pruritus and the diagnostic evaluation of pruritus are reviewed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">
          "Pruritus: Therapies for generalized pruritus"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">
          "Pruritus: Etiology and patient evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In-depth discussions of some presentations of localized pruritus are provided separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">
          "Treatment of atopic dermatitis (eczema)"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2549.html" rel="external">
          "Approach to the patient with anal pruritus"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">
          "Management of burn wound pain and itching"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1320075098">
         <span class="h1">
          GENERAL APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         The inciting factor for pruritus and extent of pruritus influence the approach to treatment. (See
         <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">
          "Pruritus: Etiology and patient evaluation", section on 'Potential causes'
         </a>
         and
         <a class="local">
          'Specific forms of localized pruritus'
         </a>
         below.)
        </p>
        <p>
         In general, management consists of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of the underlying cause (when feasible)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Elimination of aggravating factors
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pharmacologic, antipruritic therapies to reduce symptoms
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4221844826">
         <span class="h2">
          Treatment of underlying cause
         </span>
         <span class="headingEndMark">
          —
         </span>
         Successful treatment of the underlying cause of pruritus may result in resolution of symptoms [
         <a href="#rid2">
          2
         </a>
         ]. Therefore, identification and treatment of the underlying cause is advised, whenever feasible. (See
         <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">
          "Pruritus: Etiology and patient evaluation", section on 'Potential causes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H867099287">
         <span class="h2">
          Elimination of aggravating factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elimination of aggravating factors, such as dry skin, heat exposure, skin irritants, and stress, may improve pruritus. Measures to reduce exposure to these factors are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">
          "Pruritus: Therapies for generalized pruritus", section on 'Elimination of aggravating factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1371954168">
         <span class="h2">
          Selection of pharmacologic therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cause of pruritus influences the approach to pharmacologic therapy. Topical therapies are the mainstays of treatment for localized forms of pruritus and are commonly used for initial therapy  (
         <a class="graphic graphic_table graphicRef50432" href="/z/d/graphic/50432.html" rel="external">
          table 1A
         </a>
         ). Options for topical therapy include cooling agents (eg, calamine, menthol,
         <a class="drug drug_general" data-topicid="104178" href="/z/d/drug information/104178.html" rel="external">
          camphor
         </a>
         ), topical anesthetics (eg,
         <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">
          pramoxine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , compounded
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         , lidocaine), topical antihistamines (eg,
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         ), topical anti-inflammatory therapies (eg, corticosteroids, calcineurin inhibitors,
         <a class="drug drug_general" data-topicid="111394" href="/z/d/drug information/111394.html" rel="external">
          crisaborole
         </a>
         ), and topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         .
        </p>
        <p>
         Cooling agents and topical anesthetics (particularly
         <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">
          pramoxine
         </a>
         and
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ) are common first-line topical therapies, as they are widely available, generally well tolerated, and helpful for various forms of pruritus. (See
         <a class="local">
          'Cooling lotions'
         </a>
         below and
         <a class="local">
          'Topical anesthetics'
         </a>
         below.)
        </p>
        <p>
         Approaches that may be helpful for specific presentations include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inflammatory skin disorders
         </strong>
         – Topical anti-inflammatory therapies, with selection of the anti-inflammatory therapy based upon the underlying cause (see
         <a class="local">
          'Topical anti-inflammatory agents'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuropathic itch
         </strong>
         – Topical anesthetics, topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         (see
         <a class="local">
          'Topical anesthetics'
         </a>
         below and
         <a class="local">
          'Topical capsaicin'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histamine-mediated itch (eg, insect bites)
         </strong>
         – Topical antihistamines (see
         <a class="local">
          'Topical antihistamines'
         </a>
         below)
        </p>
        <p>
        </p>
        <p>
         Systemic therapies are generally incorporated when topical therapy is insufficient or impractical  (
         <a class="graphic graphic_table graphicRef63221" href="/z/d/graphic/63221.html" rel="external">
          table 1B
         </a>
         ). Oral sedating antihistamines are common initial therapies for pruritus that interferes with sleep.
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         and
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         are common initial systemic therapies for neuropathic itch. Other systemic therapies used for generalized pruritus may also be beneficial for refractory, localized pruritus. The risks and benefits of such interventions should be weighed carefully. Systemic therapies for pruritus are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">
          "Pruritus: Therapies for generalized pruritus", section on 'Role of antihistamines'
         </a>
         and
         <a class="local">
          'Peripheral neuropathic itch'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">
          "Pruritus: Therapies for generalized pruritus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2227641695">
         <span class="h1">
          ANTIPRURITIC THERAPIES
         </span>
        </p>
        <p class="headingAnchor" id="H336745018">
         <span class="h2">
          Topical therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical antipruritic therapies include cooling lotions, topical anesthetics, topical antihistamines, topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         , and topical anti-inflammatory agents.
        </p>
        <p class="headingAnchor" id="H2410419119">
         <span class="h3">
          Cooling lotions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical agents that provide a cooling sensation on the skin, such as
         <a class="drug drug_general" data-topicid="16451" href="/z/d/drug information/16451.html" rel="external">
          calamine lotion
         </a>
         or lotions containing
         <a class="drug drug_general" data-topicid="104178" href="/z/d/drug information/104178.html" rel="external">
          camphor
         </a>
         and menthol, may provide temporary relief from pruritus:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Cooling lotions may be helpful for various forms of localized pruritus and may be particularly helpful for patients who report cooling as an alleviating factor. However, there is also a subset of patients who report that cooling exacerbates itch [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale for use
         </strong>
         – Cooling sensation has an itch-relieving effect. Menthol activates the transient receptor potential TRPM8, also known as the cold receptor, contributing to antipruritic effects [
         <a href="#rid4">
          4
         </a>
         ]. The mechanism of action of
         <a class="drug drug_general" data-topicid="16451" href="/z/d/drug information/16451.html" rel="external">
          calamine lotion
         </a>
         is unknown.
         <a class="drug drug_general" data-topicid="104178" href="/z/d/drug information/104178.html" rel="external">
          Camphor
         </a>
         is a mild analgesic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Calamine lotion
         </strong>
         –
         <a class="drug drug_general" data-topicid="16451" href="/z/d/drug information/16451.html" rel="external">
          Calamine lotion
         </a>
         is shaken well immediately prior to use and applied to the affected areas as often as needed. Application of products containing both calamine lotion and
         <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">
          pramoxine
         </a>
         , a topical anesthetic, should be limited to three to four times per day. (See
         <a class="drug drug_general" href="/z/d/drug information/16451.html" rel="external">
          "Calamine lotion: Drug information"
         </a>
         and
         <a class="local">
          'Topical anesthetics'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Camphor
         </strong>
         <strong>
          and menthol
         </strong>
         – Products containing
         <a class="drug drug_general" data-topicid="104178" href="/z/d/drug information/104178.html" rel="external">
          camphor
         </a>
         and menthol are available in a variety of forms. Lotion formulations are often used for pruritus. For individuals at least two years of age, camphor and menthol lotion can be applied three to four times daily, as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Skin irritation is a potential adverse effect, and burning sensations may occur when applied to sites with skin excoriations or other superficial wounds.
         <a class="drug drug_general" data-topicid="104178" href="/z/d/drug information/104178.html" rel="external">
          Camphor
         </a>
         toxicity in children has been reported. (See
         <a class="medical medical_review" href="/z/d/html/94659.html" rel="external">
          "Camphor poisoning in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4032734923">
         <span class="h3">
          Topical anesthetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examples of topical anesthetics used for pruritus include
         <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">
          pramoxine
         </a>
         ;
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ; eutectic mixture of lidocaine and
         <a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">
          prilocaine
         </a>
         (EMLA);
         <a class="drug drug_general" data-topicid="9907" href="/z/d/drug information/9907.html" rel="external">
          polidocanol
         </a>
         ; and compounded
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         , and lidocaine  (
         <a class="graphic graphic_table graphicRef50432" href="/z/d/graphic/50432.html" rel="external">
          table 1A
         </a>
         ). Topical polidocanol is commercially available in Europe, Asia, and Australia but not in the United States:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Topical anesthetics may be helpful for various forms of localized pruritus and are considered particularly helpful for managing neuropathic itch.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale for use
         </strong>
         – Topical anesthetics exhibit antipruritic effects.
         <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">
          Pramoxine
         </a>
         1% cream, eutectic mixture of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         2.5% and
         <a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">
          prilocaine
         </a>
         2.5% cream (EMLA), and an
         <a class="drug drug_general" data-topicid="8930" href="/z/d/drug information/8930.html" rel="external">
          ethyl chloride
         </a>
         spray have demonstrated antipruritic effects in experimental settings [
         <a href="#rid5">
          5-7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinical studies have also supported the utility of topical anesthetics for pruritus. A four-week, randomized trial in 28 patients with uremic pruritus found that the percent reduction in itch intensity was greater after application of
         <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">
          pramoxine
         </a>
         1% lotion twice daily to areas of pruritus than after application of a control lotion (61 versus 12 percent reduction) [
         <a href="#rid8">
          8
         </a>
         ]. In addition, eutectic mixture of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         2.5% and
         <a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">
          prilocaine
         </a>
         2.5% (EMLA) was effective for postburn pruritus in a pilot study of five children [
         <a href="#rid9">
          9
         </a>
         ], and topical lidocaine in an acid mantle cream reduced pruritus in an uncontrolled study of 50 patients [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9907" href="/z/d/drug information/9907.html" rel="external">
          Polidocanol
         </a>
         is a nonionic surfactant primarily used for sclerotherapy that possesses both local, anaesthetic properties and moisturizing effects. An open-label study of 1611 patients with eczematous dermatitis or psoriasis found that a preparation with polidocanol and topical
         <a class="drug drug_general" data-topicid="10031" href="/z/d/drug information/10031.html" rel="external">
          urea
         </a>
         appeared to improve pruritus [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with neuropathic itch have benefited from treatment with topical anesthetics [
         <a href="#rid12">
          12,13
         </a>
         ]. In a retrospective study with 96 patients with various types of chronic itch (including 28 patients with neuropathic itch), use of compounded ketamine-amitriptyline-lidocaine was associated with improvement in symptoms [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="local">
          'Peripheral neuropathic itch'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">
          Pramoxine
         </a>
         1%, a topical anesthetic commonly used for pruritus, is available in a variety of vehicles, including lotions, gels, foams, and creams. Pramoxine is applied up to three to four times daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Instructions for topical
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         vary based upon the specific product, with application generally limited to a maximum of two to four times daily. One reported regimen consists of use of compounded 5 or 10%
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         , 5%
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         , and 5% lidocaine on limited body areas (&lt;30 percent total body surface area [TBSA]) up to three times daily [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Toxicity due to systemic absorption may occur with improper use of topical anesthetics. Methemoglobinemia is a potential consequence of EMLA use in young children. Systemic administration of
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         has been associated with multiple side effects. (See
         <a class="medical medical_review" href="/z/d/html/6338.html" rel="external">
          "Clinical use of topical anesthetics in children", section on 'Lidocaine-prilocaine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/298.html" rel="external">
          "Ketamine poisoning"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2632204090">
         <span class="h3">
          Topical antihistamines
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examples of topical antihistamines used for pruritus include
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         and
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Based upon mechanism of action, topical antihistamines are considered most appropriate for use in histamine-mediated pruritus, such as pruritus related to mosquito bites. However, topical antihistamines may also improve pruritus in other dermatologic disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Use of topical
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         is
         <strong>
          not
         </strong>
         recommended in children.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale for use
         </strong>
         – Several randomized trials support the use of topical
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         for pruritus in the setting of skin disease, such as atopic dermatitis [
         <a href="#rid14">
          14
         </a>
         ]. Data are insufficient to confirm efficacy of other topical antihistamines, including topical
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          Doxepin
         </a>
         5% cream is applied four times per day for adults; applications should be separated by at least three to four hours. Potential adverse effects of topical doxepin include drowsiness, contact dermatitis, anticholinergic effects, and stinging or burning at the site of application. Application over more than 10 percent of the body surface area (BSA) may increase risk for systemic adverse effects. (See
         <a class="drug drug_general" href="/z/d/drug information/9113.html" rel="external">
          "Doxepin (topical): Drug information"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          Diphenhydramine
         </a>
         1% or 2% cream is applied to the affected area up to three to four times per day. Potential side effects include photosensitivity, rash, and urticaria. (See
         <a class="drug drug_general" href="/z/d/drug information/9110.html" rel="external">
          "Diphenhydramine (topical): Drug information"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2624561325">
         <span class="h3">
          Topical anti-inflammatory agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Topical anti-inflammatory therapies that may be helpful for pruritus include topical corticosteroids, topical calcineurin inhibitors, and topical
         <a class="drug drug_general" data-topicid="111394" href="/z/d/drug information/111394.html" rel="external">
          crisaborole
         </a>
         (a phosphodiesterase 4 [PDE4] inhibitor):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Pruritus secondary to inflammatory, dermatologic disorders, such as atopic dermatitis, contact dermatitis, and psoriasis, can improve with topical anti-inflammatory therapies. Topical anti-inflammatory therapies are
         <strong>
          not
         </strong>
         indicated for pruritus that is not associated with cutaneous inflammation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale for use
         </strong>
         – Suppression of cutaneous inflammation often results in relief of the associated pruritus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to the suppression of cutaneous inflammation, phosphorylation of transient release potential vanilloid 1 (TRPV1) has been proposed as a mechanism through which topical calcineurin inhibitors reduce pruritus [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         PDE4 is present in a variety of inflammatory cells, including mast cells, eosinophils, neutrophils, and macrophages.
         <a class="drug drug_general" data-topicid="111394" href="/z/d/drug information/111394.html" rel="external">
          Crisaborole
         </a>
         has demonstrated anti-inflammatory and antipruritic effects for mild to moderate atopic dermatitis [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         – Topical anti-inflammatory agents are applied directly to the skin, usually once or twice daily:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical corticosteroids
         </strong>
         – Topical corticosteroids are generally applied once or twice daily. An alternative approach for thick plaques or nodular lesions is intralesional injection of corticosteroids. (See
         <a class="medical medical_review" href="/z/d/html/5568.html" rel="external">
          "Intralesional corticosteroid injection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Wet wraps applied with topical corticosteroids may be helpful for patients with significant pruritus due to a corticosteroid-responsive dermatosis, such as atopic dermatitis or other inflammatory dermatoses. Wet wraps involve the application of emollients or low- to medium-potency topical corticosteroids under moist dressings [
         <a href="#rid17">
          17,18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">
          "Treatment of atopic dermatitis (eczema)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Potential adverse effects of topical corticosteroids include cutaneous atrophy and suppression of the hypothalamic-pituitary axis. The side effects of topical corticosteroids are reviewed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5565.html" rel="external">
          "Topical corticosteroids: Use and adverse effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Topical calcineurin inhibitors
         </strong>
         – Commercially available topical calcineurin inhibitors include
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         0.03% and 0.1% ointments and
         <a class="drug drug_general" data-topicid="10162" href="/z/d/drug information/10162.html" rel="external">
          pimecrolimus
         </a>
         1% cream. These drugs are generally applied twice daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Adverse effects of topical calcineurin inhibitors include a burning sensation after application, which may be a result of initial release of substance P, as has been described with
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         [
         <a href="#rid15">
          15
         </a>
         ]. Although concern has been raised over the possibility of an increased risk for malignancy with the use of these agents, a definitive causal relationship has not been established. (See
         <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">
          "Treatment of atopic dermatitis (eczema)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Crisaborole
         </strong>
         –
         <a class="drug drug_general" data-topicid="111394" href="/z/d/drug information/111394.html" rel="external">
          Crisaborole
         </a>
         2% ointment is applied twice daily for the treatment of atopic dermatitis. Burning or stinging at the site of application is a potential adverse effect. (See
         <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">
          "Treatment of atopic dermatitis (eczema)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4082775257">
         <span class="h3">
          Topical capsaicin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          Capsaicin
         </a>
         (8-methyl-N-vanillyl-6-nonenamide) is a substance derived from chili peppers that has been used for the treatment of chronic pain and pruritus [
         <a href="#rid19">
          19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Neuropathic disorders, such as notalgia paresthetica, brachioradial pruritus, and postherpetic neuralgic itch, appear to be particularly responsive to this therapy. Prurigo nodularis, aquagenic pruritus, and pruritus associated with chronic renal disease are examples of other disorders that have been successfully treated with
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         [
         <a href="#rid19">
          19-22
         </a>
         ]. (See
         <a class="local">
          'Peripheral neuropathic itch'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rationale for use
         </strong>
         – The mechanism of action for
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         involves its ability to activate TRPV1, an ion channel in cutaneous nerve fibers [
         <a href="#rid23">
          23,24
         </a>
         ]. Activation of TRPV1 stimulates neurons to release and eventually deplete certain neuropeptides, including substance P. Capsaicin also induces lasting desensitization of neurons to a variety of stimuli. In sum, these effects lead to the inhibition of neuronal transmission of pain and pruritus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although a systematic review of randomized trials found insufficient evidence for definitive conclusions on the efficacy of
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         for pruritus [
         <a href="#rid25">
          25
         </a>
         ], multiple studies have documented the efficacy of this agent [
         <a href="#rid26">
          26-30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          Capsaicin
         </a>
         can be applied to the affected area three or four times daily. The main adverse effect of capsaicin is an initial burning sensation that can last for several days and lessens compliance. During the first two weeks of treatment, patients can apply a topical anaesthetic, such as EMLA or a
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         5% patch, 30 to 60 minutes before application of capsaicin to reduce discomfort [
         <a href="#rid19">
          19,31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3133192785">
         <span class="h2">
          Systemic therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Systemic therapies for pruritus, including oral antihistamines, antidepressants, anticonvulsants, opioid receptor antagonists, opioid receptor agonists, and other agents, are reviewed separately. (See
         <a class="local">
          'Selection of pharmacologic therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">
          "Pruritus: Therapies for generalized pruritus", section on 'Antipruritic therapies'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3478325334">
         <span class="h1">
          SPECIFIC FORMS OF LOCALIZED PRURITUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approaches to the treatment of pruritus secondary to inflammatory skin disorders, lichen simplex chronicus, burns, and various forms of peripheral neuropathic itch are reviewed here. (See
         <a class="local">
          'Inflammatory skin disorders'
         </a>
         below and
         <a class="local">
          'Lichen simplex chronicus'
         </a>
         below and
         <a class="local">
          'Burns'
         </a>
         below and
         <a class="local">
          'Peripheral neuropathic itch'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1209528246">
         <span class="h2">
          Inflammatory skin disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pruritus associated with inflammatory skin disorders often improves with successful treatment of the underlying disorder. Examples of common inflammatory skin disorders with localized involvement include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atopic dermatitis (see
         <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">
          "Treatment of atopic dermatitis (eczema)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contact dermatitis (see
         <a class="medical medical_review" href="/z/d/html/13665.html" rel="external">
          "Management of allergic contact dermatitis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1731.html" rel="external">
          "Allergic contact dermatitis in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">
          "Irritant contact dermatitis in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asteatotic, dyshidrotic, and nummular eczema (see
         <a class="medical medical_review" href="/z/d/html/1727.html" rel="external">
          "Overview of dermatitis (eczematous dermatoses)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eyelid dermatitis (see
         <a class="medical medical_review" href="/z/d/html/120320.html" rel="external">
          "Eyelid dermatitis (eczema)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psoriasis (see
         <a class="medical medical_review" href="/z/d/html/5666.html" rel="external">
          "Treatment of psoriasis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/112983.html" rel="external">
          "Psoriasis in children: Management of chronic plaque psoriasis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H45580783">
         <span class="h2">
          Lichen simplex chronicus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lichen simplex chronicus is a secondary skin disorder that results from excessive scratching. Lichenified plaques and excoriations are typically present.
        </p>
        <p>
         The treatment of lichen simplex chronicus centers on the discontinuation of the itch-scratch cycle. Commonly used therapies include topical corticosteroids under occlusion and intralesional corticosteroids.
        </p>
        <p class="headingAnchor" id="H2098745269">
         <span class="h2">
          Burns
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pruritus is a common symptom of burns. The approach to treatment of burn-related pruritus is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/14989.html" rel="external">
          "Management of burn wound pain and itching"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/349.html" rel="external">
          "Treatment of minor thermal burns"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H261894503">
         <span class="h2">
          Peripheral neuropathic itch
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of treatments have been used for brachioradial pruritus, notalgia paresthetica, and postherpetic itch. Data on the treatment of these disorders are limited.
        </p>
        <p class="headingAnchor" id="H2538838239">
         <span class="h3">
          Brachioradial pruritus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although there is some evidence that various topical and systemic antipruritic therapies can be useful for the treatment of brachioradial pruritus, further study is necessary to clarify efficacy.
        </p>
        <p>
         Our typical approach consists of using oral anticonvulsants (
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         or
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ) combined with a topical anesthetic, typically compounded
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         . In our experience, topical therapy alone is often insufficient for the intense pruritus of brachioradial pruritus. Topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         is another commonly used treatment. Topical 1% menthol may also offer some relief [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="local">
          'Topical anesthetics'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">
          "Pruritus: Therapies for generalized pruritus", section on 'Anticonvulsants'
         </a>
         .)
        </p>
        <p>
         Topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         0.025% cream was associated with symptom improvement in 13 out of 15 patients in an open-label study [
         <a href="#rid26">
          26
         </a>
         ] and in four out of seven patients in a small case series [
         <a href="#rid27">
          27
         </a>
         ]. A small, open-label study of five patients suggested sustained benefit following a single application of a capsaicin 8% patch [
         <a href="#rid33">
          33
         </a>
         ]. In contrast, a randomized trial of 13 patients with methodologic flaws showed no benefit of capsaicin 0.025% cream over a placebo cream [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Benefit of compounded
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         and
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         (with or without
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ) [
         <a href="#rid13">
          13,35
         </a>
         ],
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         [
         <a href="#rid36">
          36-40
         </a>
         ],
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         [
         <a href="#rid41">
          41,42
         </a>
         ], antidepressants [
         <a href="#rid43">
          43
         </a>
         ],
         <a class="drug drug_general" data-topicid="8590" href="/z/d/drug information/8590.html" rel="external">
          ketoprofen
         </a>
         [
         <a href="#rid44">
          44
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ] is documented in case reports or case series.
        </p>
        <p>
         Surgical intervention is an option for patients with severe, intractable symptoms who fail to improve with other therapies. Patients who have undergone surgical intervention for treatment of cervical tumor or disc herniation have reported relief of pruritus [
         <a href="#rid32">
          32,46
         </a>
         ].
        </p>
        <p>
         Cervical spine manipulation appeared beneficial in 10 out of 14 patients in one retrospective study [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H411054619">
         <span class="h3">
          Notalgia paresthetica
         </span>
         <span class="headingEndMark">
          —
         </span>
         The best approach to the treatment of notalgia paresthetica is unclear. Topical antipruritic agents, such as
         <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">
          pramoxine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         , or compounded topical
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         , and
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         , are our mainstays of treatment [
         <a href="#rid28">
          28,29,48
         </a>
         ]. We proceed to oral anticonvulsants (
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         or
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ) or injection of botulinum toxin type A when topical therapy is insufficient [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
         In a randomized, cross-over trial of 20 patients, more patients improved with topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         therapy than with vehicle (70 versus 30 percent) [
         <a href="#rid28">
          28
         </a>
         ]. However, symptoms returned after the cessation of therapy. Case reports or case series describe benefit of the topical anesthetic eutectic mixture of
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         and
         <a class="drug drug_general" data-topicid="10228" href="/z/d/drug information/10228.html" rel="external">
          prilocaine
         </a>
         (EMLA) [
         <a href="#rid12">
          12
         </a>
         ], oral
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         [
         <a href="#rid50">
          50
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Botulinum toxin A and a paravertebral nerve block have also been reported as effective in case reports [
         <a href="#rid52">
          52,53
         </a>
         ]. However, a placebo-controlled, randomized trial of 20 patients with notalgia paresthetica did not find a beneficial effect of botulinum toxin A treatment [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         Other therapies may be useful. In an observational study, transcutaneous electrical nerve stimulation led to a significant decrease in the pruritus score among 15 patients [
         <a href="#rid55">
          55
         </a>
         ]. Additionally, in a case series, four out of six patients with notalgia paresthetica and abnormalities on spinal radiograph (dorsal arthrosis or spinal static disequilibrium) improved with physiotherapy [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1742134131">
         <span class="h3">
          Postherpetic itch
         </span>
         <span class="headingEndMark">
          —
         </span>
         Herpes zoster may result in severe, prolonged pruritus that persists after resolution of the acute disease. The best approach to the treatment of postherpetic itch has not been established. Symptoms may or may not respond to treatments for postherpetic neuralgia. (See
         <a class="medical medical_review" href="/z/d/html/5289.html" rel="external">
          "Postherpetic neuralgia"
         </a>
         .)
        </p>
        <p>
         Topical anesthetics are often used for treatment [
         <a href="#rid41">
          41
         </a>
         ]. The efficacy of other agents used for neuropathic pruritus, such as topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         , and tricyclic antidepressants, are unknown. Antihistamines and topical corticosteroids are generally considered ineffective. (See
         <a class="local">
          'Topical anesthetics'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H171003115">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118799.html" rel="external">
          "Society guideline links: Pruritus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8354543">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Pruritus is a common symptom that can be incapacitating in severe cases. A wide variety of therapies have been utilized for management  (
         <a class="graphic graphic_table graphicRef50432 graphicRef63221" href="/z/d/graphic/50432.html" rel="external">
          table 1A-B
         </a>
         ); however, data are limited on the efficacy of most treatments. (See
         <a class="local">
          'General approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General approach
         </strong>
         – The inciting factor for pruritus and extent of pruritus influence the approach to treatment. (See
         <a class="local">
          'General approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Key components of therapy include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment of the underlying cause
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elimination of aggravating factors
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Antipruritic therapies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Localized pruritus, initial treatment
         </strong>
         – For patients with localized forms of pruritus, topical therapy rather than systemic therapy is often used for first-line treatment. Treatment options include cooling lotions, topical anesthetics, topical antihistamines, topical anti-inflammatory agents (eg, corticosteroids, calcineurin inhibitors,
         <a class="drug drug_general" data-topicid="111394" href="/z/d/drug information/111394.html" rel="external">
          crisaborole
         </a>
         ), and topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         . (See
         <a class="local">
          'Selection of pharmacologic therapy'
         </a>
         above and
         <a class="local">
          'Topical therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Topical corticosteroids and topical calcineurin inhibitors improve pruritus through the suppression of cutaneous inflammation in dermatologic disorders, such as atopic dermatitis or psoriasis. We suggest
         <strong>
          against
         </strong>
         using these topical anti-inflammatory agents for the treatment of pruritus unassociated with cutaneous inflammation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Topical anti-inflammatory agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Localized pruritus, refractory
         </strong>
         – Patients with localized pruritus that does not improve with treatment of the underlying disorder, elimination of aggravating factors, and topical therapy may benefit from systemic treatment. The risks and benefits of proceeding to systemic therapy should be weighed carefully. Oral sedating antihistamines are often used for initial treatment. (See
         <a class="local">
          'Selection of pharmacologic therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Brachioradial pruritus
         </strong>
         – The best approach to the treatment of brachioradial pruritus is unclear. For the initial treatment of most patients with brachioradial pruritus, we suggest an oral anticonvulsant (
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         or
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         ) and topical anesthetic rather than topical therapy alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In our experience, topical therapy alone is often insufficient. Topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         is an additional treatment option. (See
         <a class="local">
          'Brachioradial pruritus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Notalgia paresthetica
         </strong>
         – The best approach to the treatment of notalgia paresthetica is unclear. For most patients, we suggest topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         or topical anesthetics rather than systemic antipruritic therapies for initial treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          Gabapentin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         , or botulinum toxin injections are options for patients who do not improve with topical therapy. (See
         <a class="local">
          'Notalgia paresthetica'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           van Os-Medendorp H, Ros WJ, Eland-de Kok PC, et al. Effectiveness of the nursing programme 'Coping with itch': a randomized controlled study in adults with chronic pruritic skin disease. Br J Dermatol 2007; 156:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yosipovitch G, Bernhard JD. Clinical practice. Chronic pruritus. N Engl J Med 2013; 368:1625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leslie TA, Greaves MW, Yosipovitch G. Current topical and systemic therapies for itch. Handb Exp Pharmacol 2015; 226:337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palkar R, Ongun S, Catich E, et al. Cooling Relief of Acute and Chronic Itch Requires TRPM8 Channels and Neurons. J Invest Dermatol 2018; 138:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yosipovitch G, Maibach HI. Effect of topical pramoxine on experimentally induced pruritus in humans. J Am Acad Dermatol 1997; 37:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shuttleworth D, Hill S, Marks R, Connelly DM. Relief of experimentally induced pruritus with a novel eutectic mixture of local anaesthetic agents. Br J Dermatol 1988; 119:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gal-Oz A, Rogowski O, Swartzon M, Kivity S. Ethyl chloride as an antipruritic agent: a double-blind placebo-controlled prospective study. Dermatology 2010; 221:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat 2009; 20:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopecky EA, Jacobson S, Bch MB, et al. Safety and pharmacokinetics of EMLA in the treatment of postburn pruritus in pediatric patients: a pilot study. J Burn Care Rehabil 2001; 22:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           FREEMAN CW. A new topical remedy useful in the management of pruritus. J Natl Med Assoc 1961; 53:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freitag G, Höppner T. Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin. Curr Med Res Opin 1997; 13:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Layton AM, Cotterill JA. Notalgia paraesthetica--report of three cases and their treatment. Clin Exp Dermatol 1991; 16:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee HG, Grossman SK, Valdes-Rodriguez R, et al. Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability. J Am Acad Dermatol 2017; 76:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eschler DC, Klein PA. An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus. J Drugs Dermatol 2010; 9:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pereira U, Boulais N, Lebonvallet N, et al. Mechanisms of the sensory effects of tacrolimus on the skin. Br J Dermatol 2010; 163:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol 2016; 75:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bingham LG, Noble JW, Davis MD. Wet dressings used with topical corticosteroids for pruritic dermatoses: A retrospective study. J Am Acad Dermatol 2009; 60:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devillers AC, de Waard-van der Spek FB, Mulder PG, Oranje AP. Treatment of refractory atopic dermatitis using 'wet-wrap' dressings and diluted corticosteroids: results of standardized treatment in both children and adults. Dermatology 2002; 204:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papoiu AD, Yosipovitch G. Topical capsaicin. The fire of a 'hot' medicine is reignited. Expert Opin Pharmacother 2010; 11:1359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lotti T, Teofoli P, Tsampau D. Treatment of aquagenic pruritus with topical capsaicin cream. J Am Acad Dermatol 1994; 30:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breneman DL, Cardone JS, Blumsack RF, et al. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992; 26:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001; 44:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassano N, Tessari G, Vena GA, Girolomoni G. Chronic pruritus in the absence of specific skin disease: an update on pathophysiology, diagnosis, and therapy. Am J Clin Dermatol 2010; 11:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival? Clin J Pain 2008; 24:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gooding SM, Canter PH, Coelho HF, et al. Systematic review of topical capsaicin in the treatment of pruritus. Int J Dermatol 2010; 49:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knight TE, Hayashi T. Solar (brachioradial) pruritus--response to capsaicin cream. Int J Dermatol 1994; 33:206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barry R, Rogers S. Brachioradial pruritus--an enigmatic entity. Clin Exp Dermatol 2004; 29:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallengren J, Klinker M. Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study. J Am Acad Dermatol 1995; 32:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leibsohn E. Treatment of notalgia paresthetica with capsaicin. Cutis 1992; 49:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makhlough A, Ala S, Haj-Heydari Z, et al. Topical capsaicin therapy for uremic pruritus in patients on hemodialysis. Iran J Kidney Dis 2010; 4:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yosipovitch G, Maibach HI, Rowbotham MC. Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia. Acta Derm Venereol 1999; 79:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yosipovitch G, Samuel LS. Neuropathic and psychogenic itch. Dermatol Ther 2008; 21:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeidler C, Lüling H, Dieckhöfer A, et al. Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus? Br J Dermatol 2015; 172:1669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallengren J. Brachioradial pruritus: a recurrent solar dermopathy. J Am Acad Dermatol 1998; 39:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poterucha TJ, Murphy SL, Davis MD, et al. Topical amitriptyline-ketamine for the treatment of brachioradial pruritus. JAMA Dermatol 2013; 149:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bueller HA, Bernhard JD, Dubroff LM. Gabapentin treatment for brachioradial pruritus. J Eur Acad Dermatol Venereol 1999; 13:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winhoven SM, Coulson IH, Bottomley WW. Brachioradial pruritus: response to treatment with gabapentin. Br J Dermatol 2004; 150:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanitakis J. Brachioradial pruritus: report of a new case responding to gabapentin. Eur J Dermatol 2006; 16:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mataix J, Silvestre JF, Climent JM, et al. [Brachioradial pruritus as a symptom of cervical radiculopathy]. Actas Dermosifiliogr 2008; 99:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yilmaz S, Ceyhan AM, Baysal Akkaya V. Brachioradial pruritus successfully treated with gabapentin. J Dermatol 2010; 37:662.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood GJ, Akiyama T, Carstens E, et al. An insatiable itch. J Pain 2009; 10:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atış G, Bilir Kaya B. Pregabalin treatment of three cases with brachioradial pruritus. Dermatol Ther 2017; 30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wachholz PA, Masuda PY, Pinto ACVD, Martelli ACC. Impact of drug therapy on brachioradial pruritus. An Bras Dermatol 2017; 92:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott LG. Neuropathic pruritus. Australas J Dermatol 1998; 39:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crevits L. Brachioradial pruritus--a peculiar neuropathic disorder. Clin Neurol Neurosurg 2006; 108:803.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binder A, Fölster-Holst R, Sahan G, et al. A case of neuropathic brachioradial pruritus caused by cervical disc herniation. Nat Clin Pract Neurol 2008; 4:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tait CP, Grigg E, Quirk CJ. Brachioradial pruritus and cervical spine manipulation. Australas J Dermatol 1998; 39:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz M, Krause K, Maurer M, Magerl M. Treatment of notalgia paraesthetica with an 8% capsaicin patch. Br J Dermatol 2011; 165:1359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen JD, Fostini AC, Yosipovitch G. Diagnosis and Management of Neuropathic Itch. Dermatol Clin 2018; 36:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loosemore MP, Bordeaux JS, Bernhard JD. Gabapentin treatment for notalgia paresthetica, a common isolated peripheral sensory neuropathy. J Eur Acad Dermatol Venereol 2007; 21:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savk E, Bolukbasi O, Akyol A, Karaman G. Open pilot study on oxcarbazepine for the treatment of notalgia paresthetica. J Am Acad Dermatol 2001; 45:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinfeld PK. Successful treatment of notalgia paresthetica with botulinum toxin type A. Arch Dermatol 2007; 143:980.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goulden V, Toomey PJ, Highet AS. Successful treatment of notalgia paresthetica with a paravertebral local anesthetic block. J Am Acad Dermatol 1998; 38:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maari C, Marchessault P, Bissonnette R. Treatment of notalgia paresthetica with botulinum toxin A: a double-blind randomized controlled trial. J Am Acad Dermatol 2014; 70:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savk E, Savk O, Sendur F. Transcutaneous electrical nerve stimulation offers partial relief in notalgia paresthetica patients with a relevant spinal pathology. J Dermatol 2007; 34:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raison-Peyron N, Meunier L, Acevedo M, Meynadier J. Notalgia paresthetica: clinical, physiopathological and therapeutic aspects. A study of 12 cases. J Eur Acad Dermatol Venereol 1999; 12:215.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5576 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17535222" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Effectiveness of the nursing programme 'Coping with itch': a randomized controlled study in adults with chronic pruritic skin disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23614588" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical practice. Chronic pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25861788" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Current topical and systemic therapies for itch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29288650" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cooling Relief of Acute and Chronic Itch Requires TRPM8 Channels and Neurons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9270522" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effect of topical pramoxine on experimentally induced pruritus in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3191018" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Relief of experimentally induced pruritus with a novel eutectic mixture of local anaesthetic agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21099198" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Ethyl chloride as an antipruritic agent: a double-blind placebo-controlled prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18821119" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11403247" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Safety and pharmacokinetics of EMLA in the treatment of postburn pruritus in pediatric patients: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13701630" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A new topical remedy useful in the management of pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9169255" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Results of a postmarketing drug monitoring survey with a polidocanol-urea preparation for dry, itching skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1934572" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Notalgia paraesthetica--report of three cases and their treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28325395" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Topical ketamine-amitriptyline-lidocaine for chronic pruritus: A retrospective study assessing efficacy and tolerability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20684150" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : An evidence-based review of the efficacy of topical antihistamines in the relief of pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20302583" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Mechanisms of the sensory effects of tacrolimus on the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27417017" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19389521" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Wet dressings used with topical corticosteroids for pruritic dermatoses: A retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11834850" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Treatment of refractory atopic dermatitis using 'wet-wrap' dressings and diluted corticosteroids: results of standardized treatment in both children and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20446852" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Topical capsaicin. The fire of a 'hot' medicine is reignited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7507135" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Treatment of aquagenic pruritus with topical capsaicin cream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1732343" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Topical capsaicin for treatment of hemodialysis-related pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11209117" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Treatment of prurigo nodularis with topical capsaicin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20866115" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Chronic pruritus in the absence of specific skin disease: an update on pathophysiology, diagnosis, and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18209521" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Capsaicin (TRPV1 Agonist) therapy for pain relief: farewell or revival?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21128913" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Systematic review of topical capsaicin in the treatment of pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8169026" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Solar (brachioradial) pruritus--response to capsaicin cream.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15550143" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Brachioradial pruritus--an enigmatic entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7829721" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Successful treatment of notalgia paresthetica with topical capsaicin: vehicle-controlled, double-blind, crossover study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1521492" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Treatment of notalgia paresthetica with capsaicin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20404425" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Topical capsaicin therapy for uremic pruritus in patients on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10228629" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Effect of EMLA pre-treatment on capsaicin-induced burning and hyperalgesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18318883" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Neuropathic and psychogenic itch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25354282" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Capsaicin 8% cutaneous patch: a promising treatment for brachioradial pruritus?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9810902" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Brachioradial pruritus: a recurrent solar dermopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23426470" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Topical amitriptyline-ketamine for the treatment of brachioradial pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10642063" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Gabapentin treatment for brachioradial pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15099389" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Brachioradial pruritus: response to treatment with gabapentin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16709503" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Brachioradial pruritus: report of a new case responding to gabapentin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19087811" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : [Brachioradial pruritus as a symptom of cervical radiculopathy].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20629833" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Brachioradial pruritus successfully treated with gabapentin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19638326" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : An insatiable itch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28168835" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Pregabalin treatment of three cases with brachioradial pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28538902" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Impact of drug therapy on brachioradial pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9737053" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Neuropathic pruritus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16423451" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Brachioradial pruritus--a peculiar neuropathic disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18461070" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A case of neuropathic brachioradial pruritus caused by cervical disc herniation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9737043" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Brachioradial pruritus and cervical spine manipulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21711344" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Treatment of notalgia paraesthetica with an 8% capsaicin patch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29929594" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Diagnosis and Management of Neuropathic Itch.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17958872" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Gabapentin treatment for notalgia paresthetica, a common isolated peripheral sensory neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568762" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Open pilot study on oxcarbazepine for the treatment of notalgia paresthetica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17709655" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Successful treatment of notalgia paresthetica with botulinum toxin type A.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9448219" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Successful treatment of notalgia paresthetica with a paravertebral local anesthetic block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24831319" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Treatment of notalgia paresthetica with botulinum toxin A: a double-blind randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17408440" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Transcutaneous electrical nerve stimulation offers partial relief in notalgia paresthetica patients with a relevant spinal pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10461640" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Notalgia paresthetica: clinical, physiopathological and therapeutic aspects. A study of 12 cases.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
